These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 37223084)

  • 1. Bioengineering liver microtissues for modeling non-alcoholic fatty liver disease.
    Aasadollahei N; Rezaei N; Golroo R; Agarwal T; Vosough M; Piryaei A
    EXCLI J; 2023; 22():367-391. PubMed ID: 37223084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering liver microtissues for disease modeling and regenerative medicine.
    Huang D; Gibeley SB; Xu C; Xiao Y; Celik O; Ginsberg HN; Leong KW
    Adv Funct Mater; 2020 Oct; 30(44):. PubMed ID: 33390875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling nonalcoholic fatty liver disease on a liver lobule chip with dual blood supply.
    Du K; Li S; Li C; Li P; Miao C; Luo T; Qiu B; Ding W
    Acta Biomater; 2021 Oct; 134():228-239. PubMed ID: 34265474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling Nonalcoholic Fatty Liver Disease in the Dish Using Human-Specific Platforms: Strategies and Limitations.
    Rezvani M; Vallier L; Guillot A
    Cell Mol Gastroenterol Hepatol; 2023; 15(5):1135-1145. PubMed ID: 36740045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling Human Nonalcoholic Fatty Liver Disease (NAFLD) with an Organoids-on-a-Chip System.
    Wang Y; Wang H; Deng P; Tao T; Liu H; Wu S; Chen W; Qin J
    ACS Biomater Sci Eng; 2020 Oct; 6(10):5734-5743. PubMed ID: 33320545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioengineered Multicellular Liver Microtissues for Modeling Advanced Hepatic Fibrosis Driven Through Non-Alcoholic Fatty Liver Disease.
    Cho HJ; Kim HJ; Lee K; Lasli S; Ung A; Hoffman T; Nasiri R; Bandaru P; Ahadian S; Dokmeci MR; Lee J; Khademhosseini A
    Small; 2021 Apr; 17(14):e2007425. PubMed ID: 33690979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of non-alcoholic fatty liver disease progression in 3D liver microtissues using impedance spectroscopy.
    Ahn J; Ahn JH; Yoon S; Son MY; Cho S; Oh JH
    Biomaterials; 2021 Jan; 268():120599. PubMed ID: 33341736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-Dimensional Organoids as a Model to Study Nonalcoholic Fatty Liver Disease.
    Park Y; Thadasina D; Bolujo I; Isidan A; Cross-Najafi AA; Lopez K; Li P; Dahlem AM; Kennedy L; Sato K; Francis H; Alpini G; Zhang W; Ekser B
    Semin Liver Dis; 2022 Nov; 42(4):423-433. PubMed ID: 36044928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioengineering methods for organoid systems.
    Saleh J; Mercier B; Xi W
    Biol Cell; 2021 Dec; 113(12):475-491. PubMed ID: 34580889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioengineering Liver Organoids for Diseases Modelling and Transplantation.
    Li J; Chu J; Lui VCH; Chen S; Chen Y; Tam PKH
    Bioengineering (Basel); 2022 Dec; 9(12):. PubMed ID: 36551002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vitro and In Vivo Models of Non-Alcoholic Fatty Liver Disease: A Critical Appraisal.
    Soret PA; Magusto J; Housset C; Gautheron J
    J Clin Med; 2020 Dec; 10(1):. PubMed ID: 33374435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating Nonalcoholic Fatty Liver Disease in a Liver-on-a-Chip Microfluidic Device.
    Gori M; Simonelli MC; Giannitelli SM; Businaro L; Trombetta M; Rainer A
    PLoS One; 2016; 11(7):e0159729. PubMed ID: 27438262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges for the Applications of Human Pluripotent Stem Cell-Derived Liver Organoids.
    Chang M; Bogacheva MS; Lou YR
    Front Cell Dev Biol; 2021; 9():748576. PubMed ID: 34660606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gaining New Biological and Therapeutic Applications into the Liver with 3D In Vitro Liver Models.
    Lee SW; Jung DJ; Jeong GS
    Tissue Eng Regen Med; 2020 Dec; 17(6):731-745. PubMed ID: 32207030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantifying the progression of non-alcoholic fatty liver disease in human biomimetic liver microphysiology systems with fluorescent protein biosensors.
    Saydmohammed M; Jha A; Mahajan V; Gavlock D; Shun TY; DeBiasio R; Lefever D; Li X; Reese C; Kershaw EE; Yechoor V; Behari J; Soto-Gutierrez A; Vernetti L; Stern A; Gough A; Miedel MT; Lansing Taylor D
    Exp Biol Med (Maywood); 2021 Nov; 246(22):2420-2441. PubMed ID: 33957803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances.
    Lau JK; Zhang X; Yu J
    J Pathol; 2017 Jan; 241(1):36-44. PubMed ID: 27757953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental models of non-alcoholic fatty liver disease in rats.
    Kucera O; Cervinkova Z
    World J Gastroenterol; 2014 Jul; 20(26):8364-76. PubMed ID: 25024595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).
    Saeed A; Dullaart RPF; Schreuder TCMA; Blokzijl H; Faber KN
    Nutrients; 2017 Dec; 10(1):. PubMed ID: 29286303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity.
    Larsen FT; Hansen D; Terkelsen MK; Bendixen SM; Avolio F; Wernberg CW; Lauridsen MM; Grønkjaer LL; Jacobsen BG; Klinggaard EG; Mandrup S; Di Caterino T; Siersbæk MS; Indira Chandran V; Graversen JH; Krag A; Grøntved L; Ravnskjaer K
    JHEP Rep; 2023 Feb; 5(2):100615. PubMed ID: 36687468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis.
    Moore JB
    Proc Nutr Soc; 2019 Aug; 78(3):290-304. PubMed ID: 30924429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.